BACKGROUND:Atomoxetine, a selective noradrenaline reuptake inhibitor (SNRI) licensed for the treatment of attention-deficit/hyperactivity disorder (ADHD), has been shown to improve response inhibition in animals, healthy volunteers, and adult patients. However, the mechanisms by which atomoxetine improves inhibitory control have yet to be determined. METHODS: The effects of atomoxetine (40 mg) were measured with a stop-signal functional magnetic resonance imaging (fMRI) paradigm in 19 healthy volunteers, in a within-subject, double-blind, placebo-controlled design. RESULTS:Atomoxetine improved inhibitory control and increased activation in the right inferior frontal gyrus when volunteers attempted to inhibit their responses (irrespective of success). Plasma levels of drug correlated significantly with right inferior frontal gyrus activation only during successful inhibition. CONCLUSIONS: These results show that atomoxetine exerts its beneficial effects on inhibitory control via modulation of right inferior frontal function, with implications for understanding and treating inhibitory dysfunction of ADHD and other disorders.
RCT Entities:
BACKGROUND:Atomoxetine, a selective noradrenaline reuptake inhibitor (SNRI) licensed for the treatment of attention-deficit/hyperactivity disorder (ADHD), has been shown to improve response inhibition in animals, healthy volunteers, and adult patients. However, the mechanisms by which atomoxetine improves inhibitory control have yet to be determined. METHODS: The effects of atomoxetine (40 mg) were measured with a stop-signal functional magnetic resonance imaging (fMRI) paradigm in 19 healthy volunteers, in a within-subject, double-blind, placebo-controlled design. RESULTS:Atomoxetine improved inhibitory control and increased activation in the right inferior frontal gyrus when volunteers attempted to inhibit their responses (irrespective of success). Plasma levels of drug correlated significantly with right inferior frontal gyrus activation only during successful inhibition. CONCLUSIONS: These results show that atomoxetine exerts its beneficial effects on inhibitory control via modulation of right inferior frontal function, with implications for understanding and treating inhibitory dysfunction of ADHD and other disorders.
Authors: Robert Whelan; Patricia J Conrod; Jean-Baptiste Poline; Anbarasu Lourdusamy; Tobias Banaschewski; Gareth J Barker; Mark A Bellgrove; Christian Büchel; Mark Byrne; Tarrant D R Cummins; Mira Fauth-Bühler; Herta Flor; Jürgen Gallinat; Andreas Heinz; Bernd Ittermann; Karl Mann; Jean-Luc Martinot; Edmund C Lalor; Mark Lathrop; Eva Loth; Frauke Nees; Tomas Paus; Marcella Rietschel; Michael N Smolka; Rainer Spanagel; David N Stephens; Maren Struve; Benjamin Thyreau; Sabine Vollstaedt-Klein; Trevor W Robbins; Gunter Schumann; Hugh Garavan Journal: Nat Neurosci Date: 2012-06 Impact factor: 24.884
Authors: Jessica J M Barnes; Redmond G O'Connell; L Sanjay Nandam; Angela J Dean; Mark A Bellgrove Journal: Psychopharmacology (Berl) Date: 2013-08-31 Impact factor: 4.530
Authors: Eliza Congdon; Lori L Altshuler; Jeanette A Mumford; Katherine H Karlsgodt; Fred W Sabb; Joseph Ventura; James J McGough; Edythe D London; Tyrone D Cannon; Robert M Bilder; Russell A Poldrack Journal: Psychiatry Res Date: 2014-02-13 Impact factor: 3.222
Authors: Tony W Wilson; Elizabeth Heinrichs-Graham; Matthew L White; Nichole L Knott; Martin W Wetzel Journal: Neuropsychology Date: 2013-09-16 Impact factor: 3.295